[{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Copanlisib","moa":"||PI3K p110-alpha-subunit","graph1":"Oncology","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Copanlisib","moa":"||PI3K p110-alpha-subunit","graph1":"Oncology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Copanlisib","moa":"||PI3K p110-alpha-subunit","graph1":"Oncology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Columbia University","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Copanlisib","moa":"||PI3-kinase p110-delta subunit | PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase II","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Columbia University \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Columbia University \/ Bayer AG"},{"orgOrder":0,"company":"Ludwig Maximilian University of Munich","sponsor":"F. Hoffmann-La Roche | Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Copanlisib","moa":"||PI3-kinase p110-delta subunit | PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase II","graph3":"Ludwig Maximilian University of Munich","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ludwig Maximilian University of Munich \/ F. Hoffmann-La Roche | Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Ludwig Maximilian University of Munich \/ F. Hoffmann-La Roche | Bayer AG"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AbbVie Inc | Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Copanlisib","moa":"||PI3-kinase p110-delta subunit | PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ AbbVie Inc | Bayer AG","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ AbbVie Inc | Bayer AG"},{"orgOrder":0,"company":"VA Office of Research and Development","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Copanlisib","moa":"||PI3-kinase p110-delta subunit | PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"VA Office of Research and Development","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VA Office of Research and Development \/ Bayer AG","highestDevelopmentStatusID":"7","companyTruncated":"VA Office of Research and Development \/ Bayer AG"},{"orgOrder":0,"company":"Zhonglin Hao","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I","graph3":"Zhonglin Hao","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zhonglin Hao \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"Zhonglin Hao \/ Bayer AG"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Copanlisib","moa":"||PI3-kinase p110-delta subunit | PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Inhye Ahn","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Inhye Ahn","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inhye Ahn \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Inhye Ahn \/ Bayer AG"},{"orgOrder":0,"company":"University Hospital Muenster","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Copanlisib","moa":"||PI3-kinase p110-delta subunit | PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase II","graph3":"University Hospital Muenster","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital Muenster \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital Muenster \/ Bayer AG"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Copanlisib","moa":"||PI3-kinase p110-delta subunit | PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"MD Anderson Cancer Center \/ Bayer AG"},{"orgOrder":0,"company":"Brown University","sponsor":"Rhode Island Hospital | The Miriam Hospital | Bayer AG | Clovis Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Brown University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brown University \/ Rhode Island Hospital | The Miriam Hospital | Bayer AG | Clovis Oncology","highestDevelopmentStatusID":"7","companyTruncated":"Brown University \/ Rhode Island Hospital | The Miriam Hospital | Bayer AG | Clovis Oncology"},{"orgOrder":0,"company":"Columbia University","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Copanlisib","moa":"||PI3-kinase p110-delta subunit | PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase I","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Columbia University \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"Columbia University \/ Bayer AG"},{"orgOrder":0,"company":"University of Michigan Rogel Cancer Center","sponsor":"Bayer AG | Bristol Myers Squibb | University of Michigan | Big Ten Cancer Research Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Copanlisib","moa":"||PI3-kinase p110-delta subunit | PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase I","graph3":"University of Michigan Rogel Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Michigan Rogel Cancer Center \/ Bayer AG | Bristol Myers Squibb | University of Michigan | Big Ten Cancer Research Consortium","highestDevelopmentStatusID":"6","companyTruncated":"University of Michigan Rogel Cancer Center \/ Bayer AG | Bristol Myers Squibb | University of Michigan | Big Ten Cancer Research Consortium"},{"orgOrder":0,"company":"Dorothy Sipkins","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Copanlisib","moa":"||PI3-kinase p110-delta subunit | PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase I","graph3":"Dorothy Sipkins","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dorothy Sipkins \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"Dorothy Sipkins \/ Bayer AG"}]
Find Clinical Drug Pipeline Developments & Deals for Copanlisib hydrochloride
Details :
Aliqopa® (copanlisib) is a kinase inhibitor indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies and now work with the FDA on a voluntary withdrawal.
Details :
In the Phase III trial CHRONOS-3 of 458 patients with indolent non-Hodgkin’s Lymphoma, the investigational combination of Aliqopa and rituximab was statistically significant in delaying disease progression or death compared to rituximab and placebo.
Reset All
